Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review

Orit Kaidar-Person; Salem Billan; Abraham Kuten

doi:10.1007/s12032-011-9884-1

Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review

Orit Kaidar-Person, Salem Billan, Abraham Kuten

Research output: Contribution to journal › Review article › peer-review

Abstract

Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.

Original language	English
Pages (from-to)	704-706
Number of pages	3
Journal	Medical Oncology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1007/s12032-011-9884-1
State	Published - Jun 2012
Externally published	Yes

Keywords

Carcinoma
Ductal carcinoma
HER-2
Human epidermal growth factor receptor-2
Salivary gland
Targeted therapy
Trastuzumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12032-011-9884-1

Cite this

@article{bef6cdcd2f3b4435a705fb10869c483e,

title = "Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review",

abstract = "Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.",

keywords = "Carcinoma, Ductal carcinoma, HER-2, Human epidermal growth factor receptor-2, Salivary gland, Targeted therapy, Trastuzumab",

author = "Orit Kaidar-Person and Salem Billan and Abraham Kuten",

year = "2012",

month = jun,

doi = "10.1007/s12032-011-9884-1",

language = "אנגלית",

volume = "29",

pages = "704--706",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press",

number = "2",

}

TY - JOUR

T1 - Targeted therapy with trastuzumab for advanced salivary ductal carcinoma

T2 - Case report and literature review

AU - Kaidar-Person, Orit

AU - Billan, Salem

AU - Kuten, Abraham

PY - 2012/6

Y1 - 2012/6

N2 - Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.

AB - Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.

KW - Carcinoma

KW - Ductal carcinoma

KW - HER-2

KW - Human epidermal growth factor receptor-2

KW - Salivary gland

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84866326620&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-9884-1

DO - 10.1007/s12032-011-9884-1

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 21380780

AN - SCOPUS:84866326620

VL - 29

SP - 704

EP - 706

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -

Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this